

浏览全部资源
扫码关注微信
成都中医药大学 附属医院,成都 610075
Received:10 September 2020,
Published Online:18 November 2020,
Published:20 March 2021
移动端阅览
喻俊榕,郝彦伟,程敬等.基于MCT4/CD147探讨四君子汤加减改善酸性微环境逆转胃癌前病变的效应机制[J].中国实验方剂学杂志,2021,27(06):30-36.
YU Jun-rong,HAO Yan-wei,CHENG Jing,et al.Explore Mechanism of Modified Si Junzitang in Improving Acidic Microenvironment and Reversing Gastric Precancerous Lesions Based on MCT4/CD147[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(06):30-36.
喻俊榕,郝彦伟,程敬等.基于MCT4/CD147探讨四君子汤加减改善酸性微环境逆转胃癌前病变的效应机制[J].中国实验方剂学杂志,2021,27(06):30-36. DOI: 10.13422/j.cnki.syfjx.20210223.
YU Jun-rong,HAO Yan-wei,CHENG Jing,et al.Explore Mechanism of Modified Si Junzitang in Improving Acidic Microenvironment and Reversing Gastric Precancerous Lesions Based on MCT4/CD147[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(06):30-36. DOI: 10.13422/j.cnki.syfjx.20210223.
目的
2
观察四君子汤加减治疗胃癌前病变(GPL)模型大鼠胃黏膜乳酸水平及单羧酸转运蛋白1(MCT1),单羧酸转运蛋白4(MCT4)和细胞外基质金属蛋白酶诱导物(CD147)表达的影响。
方法
2
将74只SD雄性大鼠随机分为正常组12只,造模组62只。采用
N
-甲基-
N
´-硝基-
N
-亚硝基胍(MNNG)-氨水复合造模法诱导制作GPL大鼠模型,于第9周将造模组大鼠随机分为模型组,叶酸组(2.7 mg·kg
-1
),四君子汤加减高、中、低剂量组(12.6,6.3,3.15 g·kg
-1
),每组12只,灌胃治疗持续12周,观察大鼠一般情况。采用苏木素-伊红(HE)染色观察大鼠胃黏膜组织病理学改变;化学比色法检测胃黏膜组织乳酸含量;免疫组化和实时荧光定量聚合酶链式反应(Real-time PCR)检测胃黏膜组织MCT1,MCT4,CD147蛋白和mRNA表达。
结果
2
四君子汤加减可显著改善GPL大鼠胃黏膜上皮腺体结构、排列紊乱和细胞异型性等病理表现。与正常组比较,模型组大鼠胃黏膜组织乳酸含量显著升高(
P
<
0.01),MCT1,MCT4,CD147蛋白与mRNA表达均明显升高(
P
<
0.05,
P
<
0.01);与模型组比较,四君子汤加减各剂量组乳酸含量均明显降低(
P
<
0.05,
P
<
0.01),四君子汤加减高、中、低剂量组MCT4和CD147蛋白表达均显著降低(
P
<
0.05,
P
<
0.01),四君子汤加减高、中剂量组MCT4 mRNA表达明显降低(
P
<
0.05,
P
<
0.01),四君子汤加减高剂量组CD147 mRNA表达明显降低(
P
<
0.05)。四君子汤加减对MCT1无显著调控作用。
结论
2
四君子汤加减可显著改善GPL模型大鼠胃黏膜上皮异常组织病理学表现,其机制可能与下调MCT4和CD147过度表达,抑制乳酸外流,改善胃黏膜上皮酸性微环境有关。
Objective
2
To observe the effect of modified Si Junzitang on the level of lactic acid in gastric mucosa and the expression of Carboxylic acid transporter 1(MCT1), monocarboxylic acid transporter 4(MCT4), and extracellular matrix metalloproteinase inducer (CD147)in rats with gastric precancerous lesions(GPL).
Method
2
Seventy-four SD male rats were randomly divided into normal group (12 rats) and model group (62 rats).
N
-methyl-
N'
-nitro-
N
-nitrosoguanidine(MNNG)-ammonia compound method was used to establish GPL rat models, and at the 9
th
week, the model rats were randomly divided into model group, folic acid group(2.7 mg·kg
-1
), modified Si Junzitang high, medium and low dose groups(12.6, 6.3, 3.15 g·kg
-1
), with 12 rats in each group. After intragastric administration for 12 weeks, the general conditions of the rats were observed. Hematoxylin-eosin(HE)staining was used to observe the histopathological changes of gastric mucosa in rats, chemical colorimetry was used to detect the content of lactic acid in gastric mucosa; immunohistochemistry and real-time polymerase chain reaction(Real-time PCR)were used to detect MCT1, MCT4, CD147 protein and mRNA expression in gastric mucosal tissues.
Result
2
Modified Si Junzitang significantly improved the pathological manifestations in GPL rats such as gastric mucosal epithelial gland structure, disorder of arrangement and cell atypia. Compared with the normal group, the lactic acid content of the gastric mucosa tissue in the model group increased significantly(
P
<
0.01), and the protein and mRNA expressions of MCT1, MCT4, CD147 significantly increased(
P
<
0.05,
P
<
0.01). Compared with the model group, the lactic acid content in each dose group of modified Si Junzitang was significantly reduced(
P
<
0.05,
P
<
0.01), and the protein expression levels of MCT4 and CD147 were also significantly reduced in each dose group of modified Si Junzitang(
P
<
0.05,
P
<
0.01). The mRNA expression of MCT4 was significantly reduced in the middle and high dose groups(
P
<
0.05,
P
<
0.01), and the mRNA expression of CD147 was significantly reduced in the high dose group(
P
<
0.05). Modified Si Junzitang showed no significant regulatory effect on MCT1.
Conclusion
2
Modified Si Junzitang can significantly improve the abnormal histopathology of gastric mucosal epithelium in GPL model rats. Its mechanism may be related to down-regulating the overexpression of MCT4 and CD147, inhibiting lactic acid outflow, and improving the acidic microenvironment of gastric mucosal epithelium.
周晔禄 , 杨志宏 . 沈舒文辨治胃癌前病变临床经验采撷 [J]. 上海中医药杂志 , 2018 , 52 ( 6 ): 1 - 4,29 .
华秋雯 . 石丹颗粒对胃癌前病变的疗效评价及基于NF- κ B信号通路的作用机制研究 [D]. 南京 : 南京中医药大学 , 2018 .
魏玮 , 杨洋 , 史海霞 . 慢性萎缩性胃炎中医诊疗现状、挑战及展望 [J]. 中国中西医结合杂志 , 2015 , 35 ( 12 ): 1424 - 1426 .
张永欣 , 张璐 . 人乳头瘤病毒E6/E7mRNA检测在宫颈癌筛查中的意义 [J]. 中国妇幼健康研究 , 2016 , 27 ( 7 ): 816 - 818,830 .
KONG S C , N∅HR-NIELSEN A , ZEEBERG K , et al . Monocarboxylate transporters MCT1 and MCT4 regulate migration and invasion of pancreatic ductal adenocarcinoma cells [J]. Pancreas , 2016 , 45 ( 7 ): 1036 - 1047 .
PINHEIRO C , ALBERGARIA A , PAREDES J , et al . Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma [J]. Histopathology , 2010 , 56 ( 7 ): 860 - 867 .
DE OLIVEIRA A T , PINHEIRO C , LONGATTO-FILHO A , et al . Co-expression of monocarboxylate transporter 1(MCT1)and its chaperone(CD147)is associated with low survival in patients with gastrointestinal stromal tumors(GISTs) [J]. J Bioenerg Biomembr , 2012 , 44 ( 1 ): 171 - 178 .
汪婷婷 , 何永文 . 单羧酸转运蛋白家族介导乳酸转运在肿瘤发生发展中的作用 [J]. 中国肿瘤临床 , 2020 , 47 ( 7 ): 354 - 358 .
CHEN L , PAN Y , GU L , et al . ERK1/2 signalling pathway is involved in CD147-mediated gastric cancer cell line SGC7901 proliferation and invasion [J]. Exp Biol Med (Maywood) , 2013 , 238 ( 8 ): 903 - 912 .
赵彦 , 郑彩华 . 郭光业治疗慢性萎缩性胃炎经验 [J]. 河北中医 , 2014 , 36 ( 4 ): 490 - 491 .
燕东 . 姚乃礼教授治疗脾胃病学术思想及慢性胃炎辨治经验的临床研究 [D]. 北京 : 中国中医科学院 , 2016 .
郭占芳 . 四君子汤加味治疗胃癌前病变疗效分析 [J]. 中国民族民间医药 , 2011 , 20 ( 4 ): 41 .
孙方园 . 脾胃虚弱证胃癌患者术前使用四君子汤对肠内营养疗效的观察 [D]. 太原 : 山西中医药大学 , 2017 .
陈泽慧 , 魏玥 , 安静 , 等 . 慢性萎缩性胃炎及胃癌前病变大鼠造模方法的文献研究 [J]. 天津中医药 , 2019 , 36 ( 9 ): 850 - 855 .
蔡甜甜 . 胃痞消对MNNG诱导的胃癌前病变大鼠胃黏膜损伤的保护作用研究 [D]. 广州 : 广州中医药大学 , 2018 .
陈奇 . 中药药理研究方法学 [M]. 北京 : 人民卫生出版社 , 2006 : 18 .
王丽华 , 单兆伟 . 单兆伟慢性萎缩性胃炎诊疗经验浅探 [J]. 辽宁中医杂志 , 2015 , 42 ( 6 ): 1194 - 1195 .
莫喜晶 , 韦春回 , 陈国忠 . 中医药治疗慢性萎缩性胃炎癌前病变疗效的系统评价 [J]. 辽宁中医杂志 , 2013 , 40 ( 5 ): 840 - 846 .
张小倩 . 南沙参多糖的提取、降解优化及其单糖组成分析 [D]. 保定 : 河北大学 , 2014 .
张年 , 李兆星 , 李娟 , 等 . 茯苓的化学成分与生物活性研究进展 [J]. 世界科学技术—中医药现代化 , 2019 , 21 ( 2 ): 220 - 233 .
李陈雪 , 杨玉赫 , 冷德生 , 等 . 枳壳化学成分及药理作用研究进展 [J]. 辽宁中医药大学学报 , 2019 , 21 ( 2 ): 158 - 161 .
张弘 , 张连荣 , 姜海军 , 等 . 莪术醇对胃癌SGC7901细胞凋亡及AIF、Endo G表达的影响 [J]. 肿瘤学杂志 , 2015 , 21 ( 9 ): 703 - 707 .
凌汶静 . 常用抗肿瘤中药的临床应用与规律探讨 [D]. 北京 : 北京中医药大学 , 2015 .
KORNBERG M D . The immunologic Warburg effect: evidence and therapeutic opportunities in autoimmunity [J]. Wiley Interdiscip Rev Syst Biol Med , 2020 , 12 ( 5 ): e1486 .
DANG C V . Links between metabolism and cancer [J]. Genes Dev , 2012 , 26 ( 9 ): 877 - 890 .
KENNEDY K M , DEWHIRST M W . Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation [J]. Future Oncol , 2010 , 6 ( 1 ): 127 - 148 .
任筱璐 . mTOR通过上调糖酵解关键酶LDHA的表达影响肺腺癌增殖及转移的研究 [D]. 太原 : 山西医科大学 , 2020 .
尉浩斌 . 肿瘤患者肠屏障功能临床影响因素分析 [D]. 新乡 : 新乡医学院 , 2020 .
ZHANG H , CUI L , LIU W , et al . 1HNMR metabolic profiling of gastric cancer patients with lymph node metastasis [J]. Metabolomics , 2018 , 14 ( 4 ): 1 - 13 .
张宝月 , 瞿全新 , 顾安康 . CD147、MCT1及MCT4在宫颈病变中的表达及临床意义 [J]. 国际妇产科学杂志 , 2015 , 42 ( 2 ): 194 - 196 .
CAO Y W , LIU Y , DONG Z , et al . Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis [J]. Urol Oncol , 2018 , 36 ( 6 ): e15 - e25 .
HU C , DONG X , WU J , et al . CD147 overexpression may serve as a promising diagnostic and prognostic marker for gastric cancer: evidence from original research and literature [J]. Oncotarget , 2017 , 8 ( 19 ): 30888 - 30899 .
张王宁 , 李爱平 , 李科 , 等 . 中药药效物质基础研究方法进展 [J]. 中国药学杂志 , 2018 , 53 ( 10 ): 761 - 764 .
王相宜 , 张锦 , 李燕 , 等 . 肿瘤代谢调控与肿瘤免疫治疗以及代谢分析方法研究进展 [J]. 药学学报 , 2020 , 55 ( 9 ): 2080 - 2091 .
0
Views
17
下载量
4
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621